In licensing Zegfrovy, AstraZeneca has gained an already approved asset, with a label expansion potentially on the horizon.

HSBC Downgrades AstraZeneca to Hold AstraZeneca (NASDAQ:AZN) shares moved lower on Monday after HSBC downgraded the ...

With major projects spanning both manufacturing and R&D now on hold in the U.K., AstraZeneca is once again putting distance between itself and its home country. In a bid to “harmonize its share ...

AstraZeneca (AZN) is shifting its focus to the US, calling itself an "American company" on Tuesday as it ramps up manufacturing and proposes price cuts for the US market. CEO Pascal Soriot told ...

A U.S. appeals court on Thursday upheld a ruling for AstraZeneca against allegations that its ​blockbuster lung-cancer drug Tagrisso infringed patents owned by ‌Pfizer subsidiary Wyeth.

In July, AstraZeneca announced plans to invest $50 billion by 2030 on boosting its US manufacturing and research operations – Copyright AFP Tobias SCHWARZ British ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its ...

US ACT on Health Equity contributions support AstraZeneca’s long-term ambition in health equity and total more than $18 million to date AstraZeneca has proudly awarded $3.4 million to nonprofit ...

LONDON, Sept 30 (Reuters) - (This Sept. 30 story has been refiled to clarify that Wise moved its primary listing from London to New York, in paragraph 12) AstraZeneca’s (AZN.L), opens new tab move to ...